Glassia is a treatment option for individuals with severe Alpha-1 deficiency, a genetic condition that can lead to lung damage and emphysema. It is administered through intravenous infusion and can be done at a clinic, outpatient infusion center, or at home with the guidance of a healthcare provider. Glassia works by increasing the levels of the Alpha-1 antitrypsin protein in the blood and lungs, providing protection against enzyme-caused damage to lung tissue. With personalized product support and assistance programs, Glassia aims to provide tailored support for individuals undergoing Alpha-1 therapy.
Generated from the website